Description
The TS2/16 monoclonal antibody specifically recognizes CD29 which is also known as Integrin beta-1 (Integrin β1 or β1 Integrin), Glycoprotein IIa (GPIIA), Very late activation protein beta (VLA-beta; VLAB), and Fibronectin receptor subunit beta (FNRB). CD29 is an ~130 kDa single pass type I transmembrane glycoprotein that is encoded by ITGB1 (Integrin subunit beta 1). β1 integrins constitute the largest subgroup of integrins as they form noncovalent heterodimeric complexes with at least 12 different alpha integrin (Integrin α) subunits. These heterodimeric β1 integrins mediate a variety of interactions between cells and between cells and the extracellular matrix that are involved in cellular signaling, growth, survival, adhesion, and migration. The family of heterodimeric β1 integrins includes receptors for vascular cell adhesion molecule 1 (VCAM-1), extracellular matrix (ECM) components such as collagen, fibronectin, laminin, and vitronectin, and some microbial ligands. The β1 integrin subunit is widely expressed on hematopoietic and non-hematopoietic cells including T and B cells, dendritic cells (DC), NK cells, monocytes and macrophages, granulocytes, as well as mast cells, fibroblasts, endothelial cells, epithelial cells, and stem cells. Platelets express high levels of CD29 (β1 integrin) and may be bound to leucocytes from human blood. Gating out cells expressing the platelet marker CD41a will avoid attributing platelet CD29 (β1 integrin) expression to attached leucocytes. The TS2/16 antibody is reportedly useful for multiple applications including flow cytometry, immunohistochemistry, and functional studies.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
